UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 168

Sortiert nach

Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations

Clinical pharmacology and therapeutics, 2019-01, Vol.105 (1), p.229-241

2019

Link zum Volltext

Verfügbarkeit prüfen

Drug interactions with Bruton’s tyrosine kinase inhibitors: clinical implications and management

Cancer chemotherapy and pharmacology, 2020-10, Vol.86 (4), p.507-515

2020

Link zum Volltext

Verfügbarkeit prüfen

Rifampin Drug–Drug–Interaction Studies: Reflections on the Nitrosamine Impurities Issue

Clinical pharmacology and therapeutics, 2023-04, Vol.113 (4), p.816-821

2023

Link zum Volltext

Verfügbarkeit prüfen

Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestries

European journal of clinical pharmacology, 2018-07, Vol.74 (7), p.913-920

2018

Link zum Volltext

Verfügbarkeit prüfen

Effects of Strong Inhibition of Cytochrome P450 3A and UDP glucuronosyltransferase 1A9 and Strong Induction of Cytochrome P450 3A on the Pharmacokinetics, Safety, and Tolerability of Soticlestat: Two Drug-Drug Interaction Studies in Healthy Volunteers

Drug metabolism and disposition, 2024-03, Vol.52 (3), p.180

2024

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK

Journal of clinical pharmacology, 2015-09, Vol.55 (9), p.1012-1023

2015

Link zum Volltext

Verfügbarkeit prüfen

Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin

Drug metabolism and disposition, 2018-02, Vol.46 (2), p.109-121

2018

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of Safety and Clinically Relevant Drug–Drug Interactions with Tucatinib in Healthy Volunteers

Clinical pharmacokinetics, 2022-10, Vol.61 (10), p.1417-1426

2022

Link zum Volltext

Verfügbarkeit prüfen

Long‐term clinical safety of clindamycin and rifampicin combination for the treatment of hidradenitis suppurativa. A Critically Appraised Topic

British journal of dermatology (1951), 2019-04, Vol.180 (4), p.749-755

2019

Link zum Volltext

Verfügbarkeit prüfen

Clinical Pharmacokinetics of Vemurafenib

Clinical pharmacokinetics, 2017-09, Vol.56 (9), p.1033-1043

2017

Link zum Volltext

Verfügbarkeit prüfen

Predicting the Effect of CYP3A Inducers on the Pharmacokinetics of Substrate Drugs Using Physiologically Based Pharmacokinetic (PBPK) Modeling: An Analysis of PBPK Submissions to the US FDA

Clinical pharmacokinetics, 2016-04, Vol.55 (4), p.475-483

2016

Link zum Volltext

Verfügbarkeit prüfen

Physiologically based pharmacokinetic modeling and simulation to predict drug–drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia

Cancer chemotherapy and pharmacology, 2020-11, Vol.86 (5), p.619-632

2020

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects

Clinical pharmacokinetics, 2022-11, Vol.61 (11), p.1623-1639

2022

Link zum Volltext

Verfügbarkeit prüfen

Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high‐fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib

British journal of clinical pharmacology, 2017-10, Vol.83 (10), p.2242-2248

2017

Link zum Volltext

Verfügbarkeit prüfen

Investigating the Utility of Humanized Pregnane X Receptor-Constitutive Androstane Receptor-CYP3A4/7 Mouse Model to Assess CYP3A-Mediated Induction

Drug metabolism and disposition, 2021-07, Vol.49 (7), p.540-547

2021

Link zum Volltext

Verfügbarkeit prüfen

A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients

Drug metabolism and disposition, 2017-04, Vol.45 (4), p.361-374

2017

Link zum Volltext

Verfügbarkeit prüfen

Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover

European journal of pharmaceutical sciences, 2019-06, Vol.134, p.194-204

2019

Link zum Volltext

Verfügbarkeit prüfen

Physiologically-Based Pharmacokinetic Modelling of Entrectinib Parent and Active Metabolite to Support Regulatory Decision-Making

European journal of drug metabolism and pharmacokinetics, 2021-11, Vol.46 (6), p.779-791

2021

Link zum Volltext

Verfügbarkeit prüfen

Quantitative Prediction of CYP3A4 Induction: Impact of Measured, Free, and Intracellular Perpetrator Concentrations from Human Hepatocyte Induction Studies on Drug-Drug Interaction Predictions

Drug metabolism and disposition, 2017-06, Vol.45 (6), p.692-705

2017

Link zum Volltext

Verfügbarkeit prüfen

Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: Influence of time between substrate and inducer administration

European journal of pharmaceutical sciences, 2014-06, Vol.56, p.1-15

2014

Link zum Volltext

Verfügbarkeit prüfen

Everolimus dosing recommendations for tuberous sclerosis complex–associated refractory seizures

Epilepsia (Copenhagen), 2018-06, Vol.59 (6), p.1188-1197

2018

Link zum Volltext

Verfügbarkeit prüfen

Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions

Drug metabolism and disposition, 2017-04, Vol.45 (4), p.390-398

2017

Link zum Volltext

Verfügbarkeit prüfen

Concomitant use of isavuconazole and CYP3A4/5 inducers: Where pharmacogenetics meets pharmacokinetics

Mycoses, 2021-09, Vol.64 (9), p.1111-1116

2021

Link zum Volltext

Verfügbarkeit prüfen

Identification of the caffeine to trimethyluric acid ratio as a dietary biomarker to characterise variability in cytochrome P450 3A activity

European journal of clinical pharmacology, 2019-09, Vol.75 (9), p.1211-1218

2019

Link zum Volltext

Verfügbarkeit prüfen

Auto-Induction Effect of Chloroxoquinoline on the Cytochrome P450 Enzymes of Rats Associated with CYP 3A and 1A

PloS one, 2015-09, Vol.10 (9), p.e0138875

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 168

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(164)
Mit Volltextzugriff
(134)

Publikationsform

Artikel
(168)

Sprache

Englisch
(165)
Japanisch
(20)
Spanisch
(3)

Erscheinungsjahr

n.n

Thema

Humans
(154)
Science & Technology
(152)
Life Sciences & Biomedicine
(151)
Pharmacology & Pharmacy
(134)
Drug Interactions
(120)
Male
(98)
Cytochrome P-450 Cyp3a - Metabolism
(83)
Pharmacokinetics
(82)
Female
(77)
Adult
(76)
Cytochrome P-450 Cyp3a Inducers - Pharmacology
(66)
Middle Aged
(64)
Young Adult
(50)
Area Under Curve
(48)
Models, Biological
(48)
Cytochrome P-450 Cyp3a Inducers - Pharmacokinetics
(45)
Pharmacology/toxicology
(42)
Cytochrome P-450 Cyp3a Inducers - Administration & Dosage
(41)
Rifampin - Pharmacology
(41)
Cytochrome P-450 Cyp3a Inhibitors - Pharmacology
(40)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations

Drug interactions with Bruton’s tyrosine kinase inhibitors: clinical implications and management

Rifampin Drug–Drug–Interaction Studies: Reflections on the Nitrosamine Impurities Issue

Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestries

Effects of Strong Inhibition of Cytochrome P450 3A and UDP glucuronosyltransferase 1A9 and Strong Induction of Cytochrome P450 3A on the Pharmacokinetics, Safety, and Tolerability of Soticlestat: Two Drug-Drug Interaction Studies in Healthy Volunteers

Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK

Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin

Evaluation of Safety and Clinically Relevant Drug–Drug Interactions with Tucatinib in Healthy Volunteers

Long‐term clinical safety of clindamycin and rifampicin combination for the treatment of hidradenitis suppurativa. A Critically Appraised Topic

Clinical Pharmacokinetics of Vemurafenib

Predicting the Effect of CYP3A Inducers on the Pharmacokinetics of Substrate Drugs Using Physiologically Based Pharmacokinetic (PBPK) Modeling: An Analysis of PBPK Submissions to the US FDA

Physiologically based pharmacokinetic modeling and simulation to predict drug–drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia

Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects

Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high‐fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib

Investigating the Utility of Humanized Pregnane X Receptor-Constitutive Androstane Receptor-CYP3A4/7 Mouse Model to Assess CYP3A-Mediated Induction

A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients

Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover

Physiologically-Based Pharmacokinetic Modelling of Entrectinib Parent and Active Metabolite to Support Regulatory Decision-Making

Quantitative Prediction of CYP3A4 Induction: Impact of Measured, Free, and Intracellular Perpetrator Concentrations from Human Hepatocyte Induction Studies on Drug-Drug Interaction Predictions

Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: Influence of time between substrate and inducer administration

Everolimus dosing recommendations for tuberous sclerosis complex–associated refractory seizures

Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions

Concomitant use of isavuconazole and CYP3A4/5 inducers: Where pharmacogenetics meets pharmacokinetics

Identification of the caffeine to trimethyluric acid ratio as a dietary biomarker to characterise variability in cytochrome P450 3A activity

Auto-Induction Effect of Chloroxoquinoline on the Cytochrome P450 Enzymes of Rats Associated with CYP 3A and 1A

Suchergebnisse filtern